Abstract

Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous system. Most patients have a relapsing-remitting disease type, for which medicines are mostly dedicated. Clinical course of some patients will transition to secondary progressive multiple sclerosis and small portion of patients is classified as primary progressive multiple sclerosis from the beginning. The treatment of progressive multiple sclerosis has been limited for a long time, however, for a few years attention has been paid to the need for new disease modifying drugs that would focus on the treatment of progressive multiple sclerosis. The breakthrough was ocrelizumab, which is the first medicine registered in the treatment of primary progressive multiple sclerosis, while siponimod is planned to be approved soon in the treatment of secondary progressive multiple sclerosis. Numerous studies are currently underway on new substances with anti-inflammatory, neuroprotective or remyelinating effects such as high-dose biotin, ibudilast, simvastatin, alpha lipoic acid or clemastine. The first research results are very promising nevertheless, more accurate drug research is needed.

Highlights

  • Multiple sclerosis (MS) is a chronic, demyelinating, inflammatory disease of the central nervous system which multifactorial etiology [1,2]

  • The results showed that ocrelizumab significantly reduces the risk of progression of disability assessed based on Expanded Disability Status Scale (EDSS) over 12 weeks compared to placebo

  • Several studies evaluated on secondary factors have shown that there was 3.4% reduction in the number of magnetic resonance imaging (MRI) lesions in patients taking ocrelizumab, while patients taking placebo had an increase of 7.4% [14-16]

Read more

Summary

Introduction

Multiple sclerosis (MS) is a chronic, demyelinating, inflammatory disease of the central nervous system which multifactorial etiology [1,2]. The effect of high doses of simvastatin on brain atrophy in patients with SPMS was examined in the phase II double-blind, placebo-controlled clinical trial called MS-STAT. A one-step preliminary clinical trial of 16 patients with SPMS receiving 50 mg of riluzole twice daily for a year of observation showed that it may have a beneficial effect on brain atrophy and reduction of T1 hypointense lesion accumulation in cervical spine [68]. Various application methods are tested based on myelin peptide, T-cell and DNA vaccination, or antigens coupled with cells or nano-particles [72,73]

Conclusion
16. Ocrevus
Findings
34. Biotin

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.